AR028840A1 - Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contiene - Google Patents
Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contieneInfo
- Publication number
- AR028840A1 AR028840A1 ARP000103199A ARP000103199A AR028840A1 AR 028840 A1 AR028840 A1 AR 028840A1 AR P000103199 A ARP000103199 A AR P000103199A AR P000103199 A ARP000103199 A AR P000103199A AR 028840 A1 AR028840 A1 AR 028840A1
- Authority
- AR
- Argentina
- Prior art keywords
- torasemide
- polymorph
- preparation
- torasemida
- pharmaceutical form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se refiere a una forma cristalina de N-(1-metilamino carbonil)-4-(3-metil-fenilamino)-3-piridinsulfonamida, en adelante "Torasemida" y en especial a un polimorfo V de torasemida, a un proceso para su preparacion, a su utilizacion como materia prima para preparar modificaciones cristalinas I y III de torasemida, a modificaciones amorfas de torasemida, a sales de torasemida farmacéuticamente aceptables, a formas farmacéuticas que contienen dicho nuevo polimorfo V de torasemida como ingrediente activo, y a su utilizacion.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HR20000328A HRP20000328A2 (en) | 2000-05-19 | 2000-05-19 | Novel polymorph v of torasemide |
Publications (1)
Publication Number | Publication Date |
---|---|
AR028840A1 true AR028840A1 (es) | 2003-05-28 |
Family
ID=10947111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000103199A AR028840A1 (es) | 2000-05-19 | 2000-06-26 | Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contiene |
Country Status (32)
Country | Link |
---|---|
US (2) | US7241782B1 (es) |
EP (1) | EP1283828B1 (es) |
JP (1) | JP2003533512A (es) |
KR (1) | KR20030016267A (es) |
CN (1) | CN1520403A (es) |
AP (1) | AP2002002679A0 (es) |
AR (1) | AR028840A1 (es) |
AT (1) | ATE342890T1 (es) |
AU (1) | AU2000274381A1 (es) |
BG (1) | BG107407A (es) |
BR (1) | BR0015877A (es) |
CA (1) | CA2409699A1 (es) |
CZ (1) | CZ20024104A3 (es) |
DE (1) | DE60031450T2 (es) |
DZ (1) | DZ3356A1 (es) |
EA (1) | EA005003B1 (es) |
EE (1) | EE200200637A (es) |
GE (1) | GEP20043321B (es) |
HR (1) | HRP20000328A2 (es) |
HU (1) | HUP0302135A2 (es) |
IL (1) | IL152810A0 (es) |
IS (1) | IS6620A (es) |
MA (1) | MA25748A1 (es) |
MX (1) | MXPA02011402A (es) |
NO (1) | NO20025509D0 (es) |
NZ (1) | NZ522544A (es) |
PL (1) | PL358257A1 (es) |
SK (1) | SK17712002A3 (es) |
TR (1) | TR200202544T2 (es) |
WO (1) | WO2001087841A1 (es) |
YU (1) | YU84202A (es) |
ZA (1) | ZA200209181B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2002404A3 (cs) * | 1999-08-11 | 2002-06-12 | Teva Pharmaceutical Industries Ltd. | Polymorfní formy torsemidu |
IN192178B (es) * | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
US7067385B2 (en) * | 2003-09-04 | 2006-06-27 | Micron Technology, Inc. | Support for vertically oriented capacitors during the formation of a semiconductor device |
CN1824647B (zh) * | 2005-02-22 | 2011-04-20 | 田边三菱制药株式会社 | (±)2-(二甲基氨基)-1-{[O-(m-甲氧基苯乙基)苯氧基]甲基}乙基氢琥珀酸酯盐酸盐的晶体 |
CN100421662C (zh) * | 2005-11-08 | 2008-10-01 | 周卓和 | 托拉塞米分散片及其制备方法和应用 |
CN104370805B (zh) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | 托拉塞米化合物 |
CN105949115A (zh) * | 2016-05-26 | 2016-09-21 | 南京正科医药股份有限公司 | 一种新晶型托拉塞米 |
CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
CN117486789A (zh) * | 2023-12-29 | 2024-02-02 | 江西中医药大学 | 一种托拉塞米共晶盐及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1477664A (en) | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
US4055650A (en) | 1974-04-17 | 1977-10-25 | A. Christiaens Societe Anonyme | Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines |
US4476248A (en) * | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
IN182496B (es) * | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
HRP980532B1 (en) * | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
-
2000
- 2000-05-19 HR HR20000328A patent/HRP20000328A2/hr not_active Application Discontinuation
- 2000-06-26 AR ARP000103199A patent/AR028840A1/es unknown
- 2000-09-25 MX MXPA02011402A patent/MXPA02011402A/es unknown
- 2000-09-25 EP EP00962739A patent/EP1283828B1/en not_active Expired - Lifetime
- 2000-09-25 NZ NZ522544A patent/NZ522544A/en unknown
- 2000-09-25 AP APAP/P/2002/002679A patent/AP2002002679A0/en unknown
- 2000-09-25 CA CA002409699A patent/CA2409699A1/en not_active Abandoned
- 2000-09-25 KR KR1020027015607A patent/KR20030016267A/ko not_active Application Discontinuation
- 2000-09-25 DE DE60031450T patent/DE60031450T2/de not_active Expired - Fee Related
- 2000-09-25 JP JP2001584237A patent/JP2003533512A/ja active Pending
- 2000-09-25 DZ DZ003356A patent/DZ3356A1/fr active
- 2000-09-25 PL PL00358257A patent/PL358257A1/xx not_active Application Discontinuation
- 2000-09-25 YU YU84202A patent/YU84202A/sh unknown
- 2000-09-25 AU AU2000274381A patent/AU2000274381A1/en not_active Abandoned
- 2000-09-25 GE GE4998A patent/GEP20043321B/en unknown
- 2000-09-25 SK SK1771-2002A patent/SK17712002A3/sk unknown
- 2000-09-25 HU HU0302135A patent/HUP0302135A2/hu unknown
- 2000-09-25 WO PCT/HR2000/000033 patent/WO2001087841A1/en active IP Right Grant
- 2000-09-25 EA EA200201236A patent/EA005003B1/ru not_active IP Right Cessation
- 2000-09-25 AT AT00962739T patent/ATE342890T1/de not_active IP Right Cessation
- 2000-09-25 EE EEP200200637A patent/EE200200637A/xx unknown
- 2000-09-25 CZ CZ20024104A patent/CZ20024104A3/cs unknown
- 2000-09-25 TR TR2002/02544T patent/TR200202544T2/xx unknown
- 2000-09-25 BR BR0015877-1A patent/BR0015877A/pt not_active IP Right Cessation
- 2000-09-25 IL IL15281000A patent/IL152810A0/xx unknown
- 2000-09-25 US US10/276,881 patent/US7241782B1/en not_active Expired - Fee Related
- 2000-09-25 CN CNA008196567A patent/CN1520403A/zh active Pending
-
2002
- 2002-11-11 MA MA26902A patent/MA25748A1/fr unknown
- 2002-11-12 ZA ZA200209181A patent/ZA200209181B/en unknown
- 2002-11-14 IS IS6620A patent/IS6620A/is unknown
- 2002-11-15 NO NO20025509A patent/NO20025509D0/no not_active Application Discontinuation
- 2002-12-19 BG BG107407A patent/BG107407A/xx unknown
-
2007
- 2007-06-14 US US11/763,156 patent/US20070238759A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2002000321A (es) | Una nueva forma cristalina del acido n-[4-[2-(2- amino-4,7-dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin -5-il)etil]benzoil]-l-glutamico y procedimiento para su preparacion ref. x-11969 | |
IL179719A0 (en) | Process for preparation of amorphous form of drug | |
ECSP045193A (es) | "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas" | |
RS51569B (en) | COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL | |
CO5580767A2 (es) | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso | |
CL2011002925A1 (es) | Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1. | |
NI200700068A (es) | Clorhidrato de 4-[[4-[[4-(2-cianoetenil)-2,6- dimetilfenil]amino]-2- pirimidinil]amino] benzonitrilo | |
AR028840A1 (es) | Un polimorfo v de torasemida, un proceso para su preparacion y forma farmaceutica que lo contiene | |
UA96622C2 (ru) | Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования | |
PT1853232E (pt) | Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização | |
EP1314719A4 (en) | BENZOIC ACID DERIVATIVES AND MEDICAMENTS HAVING THE SAME AS ACTIVE INGREDIENT | |
UY27673A1 (es) | Procedimiento para la preparación de un producto de inhalación en polvo que contiene una sal del antagonista de cgrp, | |
NO20023551D0 (no) | Ibuprofen-inneholdende aktivt middel-preparat | |
DE60102590T2 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
GEP20156410B (en) | Formulation comprising phenylaminopyrimidine derivative as active agent | |
WO2008074833A3 (en) | Compounds | |
DK1624869T3 (da) | Doseringsform indeholdende pantoprazol som aktiv bestanddel | |
DE60131416D1 (de) | Chirale fluorochinolizinon arginine salze | |
AR023788A1 (es) | Modificacion amorfa de torasemida | |
FR2911278B1 (fr) | Procede d'obtention d'un actif cosmetique depigmentant, principe actif obtenu et compositions l'incluant | |
WO2008097539A3 (en) | Multi-modal absorption, medicine-delivery lozenge, and use thereof | |
SE0302924D0 (sv) | Pharmaceutical composition having a cationic excipient | |
DK1660495T3 (da) | Benzoquinolizin-2-carboxylsyreargininsalt,tetrahydrat | |
WO2004087102A3 (en) | A process for preparing a pharmaceutical active ingredient with high specific surface area | |
ECSP088088A (es) | Maleato de 3-[2-(dimetilamino)metil-(ciclohex-1-il)]fenol y sus formas cristalinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |